Form 8-K - Current report:
SEC Accession No. 0001851734-22-000643
Filing Date
2022-10-28
Accepted
2022-10-28 16:46:40
Documents
13
Period of Report
2022-10-28
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20221028_8k.htm   iXBRL 8-K 31068
  Complete submission text file 0001851734-22-000643.txt   163116

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20221028.xsd EX-101.SCH 3602
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20221028_def.xml EX-101.DEF 11533
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20221028_lab.xml EX-101.LAB 15415
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20221028_pre.xml EX-101.PRE 11689
7 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20221028_8k_htm.xml XML 2594
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 221342619
SIC: 2834 Pharmaceutical Preparations